Manejo, Quién?
0 likes527 views
This document discusses various factors that impact prognosis for patients with carcinomatosis peritoneal. It discusses factors like transmural invasion, number of lymph nodes analyzed, micrometastases, lymphovascular invasion, residual disease after treatment, histological grade, and the importance of multidisciplinary treatment. It provides references for studies on how each of these factors relates to patient survival outcomes.
Manejo, Quién?
- 1. Carcinomatosis.coe@gmail.com MANEJO….. ¿QUIEN? Dr. Juan Manuel Medina Castro 20 Agosto 2010 COE ISSEMyM - Toluca Carcinomatosis.coe@gmail.com
- 2. Clínica de Carcinomatosis Peritoneal Factores Pronóstico Carcinomatosis.coe@gmail.com
- 3. Clínica de Carcinomatosis Peritoneal Invasión transmural Carcinomatosis.coe@gmail.com
- 4. Clínica de Carcinomatosis Peritoneal Ganglios El número mínimo de ganglios resecados y evaluados por patología para poder afirmar o negar su involucro 12 Prandi M, Lionetto R, Bini A, et al.: Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Prognostic evaluation of stage B colon Tepper JE, O'Connell MJ, Niedzwiecki D, et al.: Colon cancer survival is associated with cancer patients is improved by an adequate Impact of number of nodes retrieved on outcome increasing number of lymph nodes analyzed: a lymphadenectomy: results of a secondary in patients with rectal cancer. J Clin Oncol 19 (1): secondary survey of intergroup trial INT-0089. J analysis of a large scale adjuvant trial. Ann 157-63, 2001 Clin Oncol 21 (15): 2912-9, 2003 Surg 235 (4): 458-63, 2002 Swanson RS, Compton CC, Stewart AK, et al.: The Colon and rectum. In: American Joint Committee Compton CC, Greene FL: The staging of prognosis of T3N0 colon cancer is dependent on on Cancer.: AJCC Cancer Staging Manual. 6th ed. colorectal cancer: 2004 and beyond. CA Cancer the number of lymph nodes examined. Ann Surg New York, NY: Springer, 2002, pp 113-124 J Clin 54 (6): 295-308, 2004 Nov-Dec Oncol 10 (1): 65-71, 2003 Jan-Feb Carcinomatosis.coe@gmail.com
- 5. Clínica de Carcinomatosis Peritoneal Micro metástasis ¿Porqué 40% de los EC II recurren? Hasta 30% de micromestástasis El estudio completo es con inmuno-histoquímica SV a 5 años 90% vs 70% (EC II) SV a 5 años 75% vs 60% (EC III) Prognostic impact of micrometastases in Prognostic value of the detection of Yasuda K,AdachiY, ShiraishiN, et al. Pattern of colon cancer: interim results of a lymph node micrometastases in lymphnode micrometastasis andprognosis prospective multicenter trial. - Bilchik AJ - colon cancer. - Bosch Roig CE - Clin of patients with colorectal cancer. Ann Surg Ann Surg - 01-OCT-2007; 246(4): 568-75; Transl Oncol - 01-SEP-2008; 10(9): Oncol 2001;8:300–4. discussion 575-7 572-8 Carcinomatosis.coe@gmail.com
- 6. Clínica de Carcinomatosis Peritoneal Invasión linfovascular Que % de patólogos lo reportan? Que % de cirujanos saben que es un FP Cual es la traducción clínica? SV a 5 años de 16% vs 3% Newland RC, Dent OF, Lyttle MN, et al. Pathologic Prognostic value of the detection of Compton CC, Fielding LP, Burgart LJ, et al. determinants of survival associated with lymph node micrometastases in Prognostic factors in colorectal cancer: College colorectal cancer with lymph node metastases: a colon cancer. - Bosch Roig CE - Clin of American Pathologists Consensus Statement multivariate analysis of 579 patients. Transl Oncol - 01-SEP-2008; 10(9): 1999. Arch Pathol Lab Med 2000;124: Cancer 1994;73:2076–82. 572-8 979–94. Carcinomatosis.coe@gmail.com
- 7. Clínica de Carcinomatosis Peritoneal Enfermedad residual Principal factor pronóstico en enfermedad avanzada. Relación inversa entre volumen de enfermedad residual y sobrevida. Compton CC, Fielding LP, Burgart LJ, et al. Swanson RS, Compton CC, Stewart AK, et al.: The Prognostic factors in colorectal cancer: College prognosis of T3N0 colon cancer is dependent on of American Pathologists Consensus Statement the number of lymph nodes examined. Ann Surg 1999. Arch Pathol Lab Med 2000;124: Oncol 10 (1): 65-71, 2003 Jan-Feb 979–94. Carcinomatosis.coe@gmail.com
- 8. Clínica de Carcinomatosis Peritoneal Enfermedad residual Cirujano general Cirujano-oncólogo Citorreducción óptima = 25-55% Citorreducción completa = 86% Citorreducción completa = 8-27% Por cada cm de citorreducción se aumenta la SV 10% Rober E Brostow, Beth Y Karlan. Ed. Taylor and Francis 2006 Carcinomatosis.coe@gmail.com
- 9. Clínica de Carcinomatosis Peritoneal Grado Histológico Wiggers T, Arends JW, Volovics A. Regression analysis of clinical and pathological factors in colorectal cancer after curative resections. Dis Colon Rectum 1988;31:33–41. Carcinomatosis.coe@gmail.com
- 10. Clínica de Carcinomatosis Peritoneal ¿Quien? Aquel que conozca al cáncer Aquel que ofrezca el tratamiento completo Aquel que trabaje multidisciplinariamente Nelson H, Petrelli N, Carlin A, et al.: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93 (8): 583-96, 2001 Carcinomatosis.coe@gmail.com
- 11. Clínica de Carcinomatosis Peritoneal Carcinomatosis.coe@gmail.com
- 12. GRACIAS Carcinomatosis.coe@gmail.com Carcinomatosis.coe@gmail.com